Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases

Abstract Parkinson’s disease (PD) exhibits substantial phenotypic variability, likely influenced, at least in part, by proteins associated with pathways integral to aging processes. Plasminogen activator inhibitor-1 (SERPIN E1) is known for its association with aging processes and exacerbated α-Synu...

Full description

Saved in:
Bibliographic Details
Main Authors: Milan Zimmermann, Madeleine Fandrich, Meike Jakobi, Benjamin Röben, Isabel Wurster, Stefanie Lerche, Claudia Schulte, Shahrzad Zimmermann, Christian Deuschle, Nicole Schneiderhan-Marra, Thomas O. Joos, Thomas Gasser, Kathrin Brockmann
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-025-00984-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850221928040628224
author Milan Zimmermann
Madeleine Fandrich
Meike Jakobi
Benjamin Röben
Isabel Wurster
Stefanie Lerche
Claudia Schulte
Shahrzad Zimmermann
Christian Deuschle
Nicole Schneiderhan-Marra
Thomas O. Joos
Thomas Gasser
Kathrin Brockmann
author_facet Milan Zimmermann
Madeleine Fandrich
Meike Jakobi
Benjamin Röben
Isabel Wurster
Stefanie Lerche
Claudia Schulte
Shahrzad Zimmermann
Christian Deuschle
Nicole Schneiderhan-Marra
Thomas O. Joos
Thomas Gasser
Kathrin Brockmann
author_sort Milan Zimmermann
collection DOAJ
description Abstract Parkinson’s disease (PD) exhibits substantial phenotypic variability, likely influenced, at least in part, by proteins associated with pathways integral to aging processes. Plasminogen activator inhibitor-1 (SERPIN E1) is known for its association with aging processes and exacerbated α-Synuclein pathology. We examined whether SERPIN E1 levels in cerebrospinal fluid (CSF) differ among controls (CON, N = 16) and patients with PD (N = 479) or Dementia with Lewy bodies (DLB, N = 67), considering that these conditions represent a spectrum of α-Synuclein pathology. Kaplan-Meier survival analysis stratified by SERPIN E1 tertile levels was conducted to evaluate phenotype-modifying effects. Elevated levels of SERPIN E1 exhibited an association with increased age and lower MOCA scores. Heightened SERPIN E1 levels were observed in individuals diagnosed with DLB, followed by PD and CON, and in males compared to females. The quantification of SERPIN E1 in CSF could potentially serve as a surrogate marker, depicting (pathological) aging processes.
format Article
id doaj-art-e893803e4a874cef8c399872c080aa23
institution OA Journals
issn 2373-8057
language English
publishDate 2025-06-01
publisher Nature Portfolio
record_format Article
series npj Parkinson's Disease
spelling doaj-art-e893803e4a874cef8c399872c080aa232025-08-20T02:06:31ZengNature Portfolionpj Parkinson's Disease2373-80572025-06-011111910.1038/s41531-025-00984-3Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseasesMilan Zimmermann0Madeleine Fandrich1Meike Jakobi2Benjamin Röben3Isabel Wurster4Stefanie Lerche5Claudia Schulte6Shahrzad Zimmermann7Christian Deuschle8Nicole Schneiderhan-Marra9Thomas O. Joos10Thomas Gasser11Kathrin Brockmann12Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenNMI Natural and Medical Sciences Institute at the University of TuebingenNMI Natural and Medical Sciences Institute at the University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenNMI Natural and Medical Sciences Institute at the University of TuebingenNMI Natural and Medical Sciences Institute at the University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenDepartment of Neurodegeneration and Hertie-Institute for Clinical Brain Research, Center of Neurology, University of TuebingenAbstract Parkinson’s disease (PD) exhibits substantial phenotypic variability, likely influenced, at least in part, by proteins associated with pathways integral to aging processes. Plasminogen activator inhibitor-1 (SERPIN E1) is known for its association with aging processes and exacerbated α-Synuclein pathology. We examined whether SERPIN E1 levels in cerebrospinal fluid (CSF) differ among controls (CON, N = 16) and patients with PD (N = 479) or Dementia with Lewy bodies (DLB, N = 67), considering that these conditions represent a spectrum of α-Synuclein pathology. Kaplan-Meier survival analysis stratified by SERPIN E1 tertile levels was conducted to evaluate phenotype-modifying effects. Elevated levels of SERPIN E1 exhibited an association with increased age and lower MOCA scores. Heightened SERPIN E1 levels were observed in individuals diagnosed with DLB, followed by PD and CON, and in males compared to females. The quantification of SERPIN E1 in CSF could potentially serve as a surrogate marker, depicting (pathological) aging processes.https://doi.org/10.1038/s41531-025-00984-3
spellingShingle Milan Zimmermann
Madeleine Fandrich
Meike Jakobi
Benjamin Röben
Isabel Wurster
Stefanie Lerche
Claudia Schulte
Shahrzad Zimmermann
Christian Deuschle
Nicole Schneiderhan-Marra
Thomas O. Joos
Thomas Gasser
Kathrin Brockmann
Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases
npj Parkinson's Disease
title Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases
title_full Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases
title_fullStr Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases
title_full_unstemmed Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases
title_short Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases
title_sort elevated cerebrospinal fluid levels of serpin e1 in participants with lewy body diseases
url https://doi.org/10.1038/s41531-025-00984-3
work_keys_str_mv AT milanzimmermann elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT madeleinefandrich elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT meikejakobi elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT benjaminroben elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT isabelwurster elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT stefanielerche elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT claudiaschulte elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT shahrzadzimmermann elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT christiandeuschle elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT nicoleschneiderhanmarra elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT thomasojoos elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT thomasgasser elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases
AT kathrinbrockmann elevatedcerebrospinalfluidlevelsofserpine1inparticipantswithlewybodydiseases